XLO
NASDAQ HealthcareXilio Therapeutics, Inc. - Common Stock
Biotechnology
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
๐ Market Data
| Price | $9.03 |
|---|---|
| Volume | 115,867 |
| Market Cap | 59.37M |
| Beta | -0.120 |
| RSI (14-Day) | 53.1 |
| 200-Day MA | $9.07 |
| 50-Day MA | $8.52 |
| 52-Week High | $12.74 |
| 52-Week Low | $6.47 |
| Forward P/E | -15.57 |
| Price / Book | 1.16 |
๐ฏ Investment Strategy Scores
XLO scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (62/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Institutional Whale (1/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find XLO in your text
Paste any article, transcript, or post โ the tool will extract XLO and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.